Name (Synonyms) | Correlation |
---|
There is one clinical trial.
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone. Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.
Description: After being admitted, patient was monitored whether he does not required to be transferred in ICU or died because of a severe COVID-19 pneumonia within 7 days. The outcome was purely clinical. If patient was discharged at home after admission and/or was transferred into a rehabilitation center he was considered as a favorable outcome independently of any biological marker.
Measure: Favorable outcome Time: Assessed within 7 days after admissionDescription: Studying if biological abnormalities (lymphocyte count or CRP) at admission were associated with an unfavorable outcome
Measure: Risk factors 1 Time: Assessed at day 1Description: Studying if comorbidities were associated with an unfavorable outcome
Measure: Risk factors 2 Time: Assessed at day 1Description: Studying whether any regimen was associated with a favorable outcome (including azithromycin)
Measure: Interest of anti-infective agents Time: From date of inclusion until the date of first documented progression to ICU or date of death from any cause, whichever came first, assessed up to 2 months